Industry Sponsored Satellite Symposia ISAL XVII 2019
(Companies in alphabetical order)
Abbvie Deutschland GmbH (Gold Circle Member)
Satellite Symposium II: Sunday, February 24, 2019: 18.15 -19.15 (Lecture Hall III/IV)
„Changing the goals in AML: Optimizing Therapeutic Approaches for the Older Patients“
18.15-18.25
U. Platzbecker, Leipzig, DE
Welcome and introduction
- Setting the scene
- The changing landscape in AML
- Defining treatment goals and therapeutic approaches in the older patient with AML
18.25-18.40
NN
Emerging agents for the treatment of patients with AML
- Overview of potential targets/pathways
- Targeted therapies – FLT3 and IDH inhibitors (focus on agents that are currently available, or will be available in the near-future)
- BCL-2 inhibition with venetoclax
18.40-18.55
U. Platzbecker, Leipzig, DE
Strategies to overcome resistance
- Mechanisms of resistance to conventional therapy
- Role of LSCs in resistance and relapse (data on overexpression of BCL-2 in LSCs to be included)
- Combination strategies to prevent and overcome resistance (e.g. HMA + targeted agents)
18.55-19.05
NN
From bench to bedside: Practical considerations for the older patient with AML
- Management of adverse events
- Patient compliance
- Expert opinion
19.05-19.10
Audience Q&A
19.10-19.15
Summary and Close
Amgen GmbH (Gold Circle Member)
Satellite Symposium I: Sunday, February 24, 2019: 17.00 -18.00 (Lecture Hall III/IV)
„Targeted Therapy of Acute Leukemia: Present Achievements and Future Potential“
17.00-17.05
M.Topp, Würzburg, DE
Welcome and Introduction
17.05-17.30
M. Topp, Würzburg, DE
The Present: T-Cell Engaging Immunotherapy for ALL
17.30-17.55
M. Subklewe, Munich, DE
The Future: Bispecific Antibody Constructs for the Treatment of AML
17.55-18.00
M. Subklewe, Munich, DE
Closing Remarks
Astellas Pharma (Gold Circle Member)
Satellite Symposium VI: Tuesday, February 26, 2019: 13.00 -14.00 (Lecture Hall III/IV)
„Progress in AML: The Present and the Future“
Chair:
L. Bullinger, Berlin, DE
13.00-13.05
L. Bullinger, Berlin, DE
Welcome and Introduction
13.05-13.20
K. Götze, Munich, DE
Progress in AML: The Present
13.25-13.45
Th. Schröder, Düsseldorf, DE
Progress in AML: The Future
13.45-14.00
L. Bullinger, Berlin, DE
Discussion and Conclusion – All
Celgene GmbH (Gold Circle Member)
Satellite Symposium VII: Tuesday, February 26, 2019: 16.30 – 17.30 (Lecture Hall III/IV)
„Deciphering AML complexities: Prognosis and Treatment“
Chair:
K. Metzeler, Munich, DE
16.30-16.35
K. Metzeler, Munich, DE
Welcome and Introduction
16.35-17.00
K. Döhner, Ulm, DE
How do Genetics of AML Patients influence Prognosis, Treatment Strategies and Follow-Up Today and Tomorrow?
17.00-17.25
H. Dombret, Paris, F
What Expectations do we have of AML Treatment beyond Complete Remission?
17.25-17.30
Discussion and Close
Daiichi Sankyo (Gold Circle Member)
Satellite Symposium IV: Monday, February 25, 2019: 17.00 -18.00 (Lecture Hall III/IV)
„FLT3/Targeted Therapy / Future of AML Therapy“
Chair:
W. Hiddemann, Munich, DE
17.00-17.05
W. Hiddemann, Munich DE
Welcome and Introduction
17.05-17.25
R. Schlenk, Heidelberg, DE
Targeted Therapy in AML: What do the Guidelines tell us?
17.25-17.45
M.J. Levis, Baltimore, USA
Targeted Therapy in AML: Where does the Science guide us?
17.50-18.00
W. Hiddemann, Munich, DE
Panel Discussion and Closing Remarks
Jazz Pharmaceuticals Germany GmbH (Gold Circle Member)
Satellite Symposium III: Monday, February 25, 2019: 12.45 – 13.45 (Lecture Hall III/IV)
„High-Risk AML: WHO Knows? Improving Outcomes in these Patients“
12.45-12.50
L. Bullinger, Berlin, DE
Welcome and Introduction
12.50-13.10
L. Bullinger, Berlin, DE
Diagnosing High-Risk AML: *WHO and What?
- Clinical and Biological Heterogeneity of AML (Cytogenetics and Genomics)
- Overview of different classification systems
- Therapy related AML (t-AML)
o Pathogenesis, clinical and genomic features, prognosis - AML with Myelodysplasia Related Changes (AML-MRC)
o WHO 2016 classification
o Pathogenesis, clinical and genomic features, prognosis
13.10-13.30
M.S.Tallman, New York, NY, USA
Improving Outcomes in High-Risk AML
- Patient Case Study
- trial Data Included Throughout Presentation
13.30-13.45
Q & A
Pfizer GmbH (Gold Circle Member)
Satellite Symposium VIII: Tuesday, February 26, 2019: 17.45 – 18.45 (Lecture Hall III/IV)
„Changing Treatment Landscape in AML“
Chair:
L. Bullinger, Berlin, DE
17.45-17.50
L. Bullinger, Berlin, DE
Welcome
17.50-18.10
M. Subklewe, Munich, DE
Gemtuzumab Ozogamicin in de novo AML
18.10-18.15
Q & A
18.15-18.35
C. Müller-Tidow, Heidelberg, DE
Emerging Treatment Strategies in AML
18.35-18.40
Q & A
18.40-18.45
L. Bullinger, Berlin, DE
Conclusion
Vector Therapeutics (Bronze Circle Member)
EVENING SYMPOSIUM: Monday, February 25, 2019: 20.00-21.00 LeMeridien
(A free-of-charge Shuttle Bus Service will be available for all participants joining the Evening Symposium at LeMeridien after the end of Satellite V starting from the symposium venue (Back entrance Hörsaaltrakt; Details will be announced on site)
„Preventing AML Relapse: The Role of Immunotherapy“
Chair:
W. Hiddemann, Munich, DE
19.30 -20.00
Welcome Reception – Drinks & Food
20.00 -20.10
W. Hiddemann, Munich, DE
Introduction
20.10-20.25
Anna Martner, Gothenburg, SE
Highlights & Key Results: Immune Activation during Immunotherapy with Ceplene/IL-2 Implications for Relapse risk and Survival in AML
20.25-20.40
Kristoffer Hellstrand, Gothenburg, SE
Highlights & Key results: Relapse Prevention by Ceplene/IL-2 in Molecular Subgroups of AML
20.40 -21.00
W. Hiddemann, Munich, DE
Roundtable / Panel Discussion
CLOSING REMARKS
PLEASE REGISTER via: vectortherapeutics-symposium@iqvia.com